Remove Gene Remove Generic Drugs Remove Hormones
article thumbnail

Top 40 Best-Selling Oncology Drugs in 2023 by 2022 Data

XTalks

Alecensa is approved in Japan for the additional indication of recurrent or refractory ALK fusion gene-positive anaplastic large-cell lymphoma. Alecensa is not currently available in generic form. million the drug made during the same time in 2022. For the first three quarters of 2023, worldwide Alimta revenue was $172.6

article thumbnail

Top 40 Best-Selling Cancer Drugs in 2023 by 2022 Data

XTalks

Alecensa is approved in Japan for the additional indication of recurrent or refractory ALK fusion gene-positive anaplastic large-cell lymphoma. Alecensa is not currently available in generic form. million the drug made during the same time in 2022. For the first three quarters of 2023, worldwide Alimta revenue was $172.6

article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. It is a CDK 4/6 inhibitor that is taken in combination with other hormonal therapies to stop the growth of cancer and healthy cells.

Sales 98